Atopic dermatitis
Conditions
Interventions
None listed
Sponsors
Institute of Science Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Study [1] [Atopic dermatitis(AD) patients] 1. AD patients who have visited Department of Dermatology in Tokyo Medical and Dental University (TMDU) Hospital and who meet the diagnostic criteria of Japanese Dermatological Association 2. Patients for whom skin biopsy is required to differentiate from other diseases or patients who have undergone skin biopsy within 2 years prior to the date of informed consent 3. Patients aged 20 years or older at the time of informed consent (men and women) 4. Patients who have been fully informed of and fully understand the study contents before providing written voluntary consent [Healthy adults] 1. Healthy volunteers aged 20 years or older at the time of informed consent (men and women) 2. Those who have been confirmed not to have any disease by interview 3. Those who have been fully informed of and fully understand the study contents before providing written voluntary consent Study [2] [Healthy adults] 1. Healthy volunteers aged 20 years or older at the time of informed consent (men and women) 2. Patients who have been fully informed of and fully understand the study contents before providing written voluntary consent
Exclusion criteria
Exclusion criteria: Study [1] [AD patients] 1. Patients who have received immunosuppressants including high-dose steroids (predonine-equivalent dose over 10mg/day) within 3 months prior to the enrollment 2. Patients who have been treated with anti IL-4 receptor antibody, oral JAK inhibitor, anti IgE antibody, and PDE4 inhibitor within 3 months prior to the enrollment 3. Patients who have not been able to stop using topical agents (except moisturizers) on the biopsy site from 3 days prior to the skin biopsy 4. Patients with serious physical/mental conditions 5. Pregnant and lactating women, or women who are possibly pregnant. 6. Patients who have been determined by a physician who is the investigator, etc. to be ineligible for the study for any other reason [Healthy adults] 1. Patients who have history of serious diseases or AD 2. Pregnant and lactating women, or women who are possibly pregnant. 3. Personnel and students from the Department of Inflammation, Infection and Immunity Laboratory, Advanced Research Institute, TMDU or Department of Dermatology, TMDU Study [2] [Healthy adults] 1. Patients who have history of complication of serious diseases 2. Those who have obvious symptoms of anaemia (conjunctival pallor, etc.) 3. Men: Those who have donated blood (blood sampling) at a volume of over 400 mL within 3 months and 1200 mL within 1year 4. Women: Those who have donated blood (blood sampling) at a volume of over 400 mL within 4 months and 800 mL within 1year 5. Pregnant and lactating women, or women who are possibly pregnant. 6. Those who have been determined by a physician who is the investigator, etc. to be ineligible as the subject of the study for any other reason 7. Personnel and students from the Department of Inflammation, Infection and Immunity Laboratory, Advanced Research Institute, TMDU or Department of Dermatology, TMDU
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of PDE4 in basophils derived from skin tissues will be investigated in patients with atopic dermatitis. | — |
Countries
Japan
Contacts
Public ContactKensuke Miyake
Institute of Science Tokyo Institute of Integrated Research
Outcome results
None listed